Exubera filed in Europe; U.S. plans?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Aventis and Pfizer are "working with [FDA] to determine the appropriate timing for submission of the Exubera [NDA] in the U.S.," according to Aventis. The firms announced submission of a marketing authorization application for their inhaled insulin product with the European Medicines Evaluation Agency March 4, for treatment of type 1 and 2 diabetes...
You may also be interested in...
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.